Effective targeted therapy necessitates the presence of specific proteins or genetic alterations, hence it commonly targets molecular entities intricately linked to CRC initiation and progression like EGFR and VEGF (Li et al., 2023b) with ongoing exploration of numerous additional targets (Grassilli and Cerrito, 2022). The gene discussed is EGFR; the disease is colorectal carcinoma.